{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+Interferon+Beta", "query": { "intervention": "Recombinant Interferon Beta" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 118, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+Interferon+Beta&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T01:54:38.118Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02294058", "title": "Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ozanimod", "type": "DRUG" }, { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Placebo to ozanimod", "type": "DRUG" }, { "name": "Placebo to interferon beta-1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1346, "start_date": "2014-12-03", "completion_date": "2016-12-22", "has_results": true, "last_update_posted_date": "2020-11-25", "last_synced_at": "2026-09-05T01:54:38.118Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02294058" }, { "nct_id": "NCT00299962", "title": "Gene Therapy for Pleural Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pleural Mesothelioma", "Metastatic Pleural Effusions" ], "interventions": [ { "name": "Adenoviral-mediated Interferon-beta", "type": "BIOLOGICAL" }, { "name": "SCH 721015", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2006-03", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2020-03-18", "last_synced_at": "2026-09-05T01:54:38.118Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00299962" }, { "nct_id": "NCT03647163", "title": "Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non Small Cell Lung Cancer", "Neuroendocrine Carcinoma", "Renal Cell Carcinoma (RCC)" ], "interventions": [ { "name": "VSV-IFNβ-NIS", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "ipilimumab + nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vyriad, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2019-04-09", "completion_date": "2025-09-30", "has_results": false, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-09-05T01:54:38.118Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Cleveland, Ohio", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03647163" }, { "nct_id": "NCT00002299", "title": "The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cytomegalovirus Retinitis", "HIV Infections" ], "interventions": [ { "name": "Interferon beta-1b", "type": "DRUG" }, { "name": "Ganciclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-05T01:54:38.118Z", "location_count": 6, "location_summary": "Los Angeles, California • Orange, California • San Diego, California + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002299" }, { "nct_id": "NCT01500408", "title": "Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Interferon beta-1a (current approved manufacturing process invloving FBS)", "type": "DRUG" }, { "name": "Interferon beta-1a (new process, manufactured without FBS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 110, "start_date": "2012-01", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2012-11-19", "last_synced_at": "2026-09-05T01:54:38.118Z", "location_count": 1, "location_summary": "Saint Paul, Minnesota", "locations": [ { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01500408" }, { "nct_id": "NCT00811395", "title": "Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Teriflunomide", "type": "DRUG" }, { "name": "Placebo (for teriflunomide)", "type": "DRUG" }, { "name": "Interferon-β [IFN-β]", "type": "DRUG" }, { "name": "Glatiramer Acetate [GA]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 182, "start_date": "2007-10", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2012-12-31", "last_synced_at": "2026-09-05T01:54:38.118Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00811395" }, { "nct_id": "NCT01071083", "title": "Treatment Interruption of Natalizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsing Remitting Multiple Sclerosis" ], "interventions": [ { "name": "natalizumab", "type": "DRUG" }, { "name": "interferon beta 1-a", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "IV placebo", "type": "OTHER" }, { "name": "glatiramer acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 175, "start_date": "2010-03", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2013-09-19", "last_synced_at": "2026-09-05T01:54:38.118Z", "location_count": 20, "location_summary": "Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Pompano Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01071083" }, { "nct_id": "NCT05688436", "title": "A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Diroximel Fumarate", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "BIOLOGICAL" }, { "name": "Fingolimod", "type": "DRUG" }, { "name": "Glatiramer acetate", "type": "DRUG" }, { "name": "Interferon beta", "type": "BIOLOGICAL" }, { "name": "Natalizumab", "type": "BIOLOGICAL" }, { "name": "Ocrelizumab", "type": "BIOLOGICAL" }, { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Ozanimod", "type": "DRUG" }, { "name": "Peginterferon beta-1a", "type": "BIOLOGICAL" }, { "name": "Ponesimod", "type": "DRUG" }, { "name": "Siponimod", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 1178, "start_date": "2021-09-24", "completion_date": "2031-01-17", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-05T01:54:38.118Z", "location_count": 1, "location_summary": "Eden Prairie, Minnesota", "locations": [ { "city": "Eden Prairie", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05688436" }, { "nct_id": "NCT00324506", "title": "Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Mycophenolate Mofetil (CellCept)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 43, "start_date": "2006-05", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-09-05T01:54:38.118Z", "location_count": 3, "location_summary": "Farmington Hills, Michigan • Buffalo, New York • Dallas, Texas", "locations": [ { "city": "Farmington Hills", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324506" }, { "nct_id": "NCT00490906", "title": "Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis", "Low Bone Density" ], "interventions": [ { "name": "Copaxone", "type": "DRUG" }, { "name": "Interferon-beta 1a", "type": "DRUG" }, { "name": "Interferon-beta 1b", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nancy Hammond, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2007-06", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2014-01-22", "last_synced_at": "2026-09-05T01:54:38.118Z", "location_count": 2, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00490906" } ] }